Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Net cash inflow of $13.4 million from recent registered direct offering and warrant exercises AM-301 program progressing towards clinical and regulatory milestones Strategy review ongoing Hamilton,...
-
Hamilton, Bermuda, December 7, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
-
Hamilton, Bermuda, December 2, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS) (“Auris” or the “Company”), a clinical-stage company dedicated to developing therapeutics that address important unmet...
-
Up to 99.4% reduction of viral titer in human epithelial cell culture (p<0.001)Results suggest potential for AM-301 nasal spray to mitigate risk of Sars-CoV-2 infection Hamilton, Bermuda, December...
-
Hamilton, Bermuda, November 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
-
Hamilton, Bermuda, October 13, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
-
Advancing Phase 2 trial with AM-125 in acute vertigo based on positive interim dataPositive outcome from AM-201 trial in prevention of antipsychotic-induced weight gainAddition of new intranasal...
-
Hamilton, Bermuda, September 11, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
-
Development of AM-301 nasal spray initiated with aim of regulatory submission in 2021Key component of AM-301 shown to reduce SARS-CoV-2 viral infectious load in vitro by up to 99%Creation of dedicated...
-
Dose dependent improvement in balance tests over placebo in Part A of TRAVERS trialImprovement 1.9 to 2.4 times greater with highest dose than with placeboTrial to proceed with Part B to test AM-125...